Randomized Double-Blind Controlled Clinical Trial Comparing Sodium Hypochlorite Antiseptic to Normal Saline in Reducing Bioburden in Wounds
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Wounds
- Sponsor
- SerenaGroup, Inc.
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Reduction in bacterial bioburden
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The study is a randomized double-blind controlled clinical trial designed to compare the ability of NaOCl to NSS in the reduction of bacterial burden in nonhealing acute and chronic wounds.
Detailed Description
The study is a randomized double-blind controlled clinical trial designed to compare the ability of NaOCl to NSS in the reduction of bacterial burden in nonhealing acute and chronic wounds. Using the generally accepted surrogate endpoint of surface area reduction at 4 weeks, the study will also compare the healing of subjects utilizing NaOCl vs. NSS. After consenting, the ulcers of eligible subjects are measured, photographed and undergo the MolecuLight imaging procedure (MiX). The subject is then randomized to one of two arms: target ulcer cleansed with NaOCl or NSS. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of either NaOCl or NSS.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients with acute or chronic wounds that have been present for a minimum of 4 weeks.
- •A signed and dated informed consent form.
- •Subject is willing and able to comply with instructions and scheduled visits.
Exclusion Criteria
- •The Subject has other concurrent conditions that in the opinion of the Investigator may compromise subject safety.
- •The subject's wound has not been present for at least 4 weeks.
Outcomes
Primary Outcomes
Reduction in bacterial bioburden
Time Frame: 4 weeks
The reduction in bacterial bioburden as determined by the MolecuLight Procedure (MiX) between normal saline (NSS) and sodium hypochlorite (NaOCl) wound washing.
Secondary Outcomes
- Adverse Events(4 weeks)
- Healing rate(4 weeks)
- Pain Score (PEG)(4 weeks)